同仁堂(600085) - 同仁堂投资者关系活动记录表

Group 1: Product Strategy - The company has launched the "Royal Medicine Legend Series" as a premium product line, with initial sales meeting expectations in key provinces and cities [2] - The premium product series is currently in an exploratory phase, contributing a small proportion to overall business scale [2] - The company plans to introduce a second batch of premium products based on market feedback to meet diverse consumer needs [2] Group 2: Market Reach and Distribution - The company is enhancing its marketing reform by strengthening its own channel construction and gradually expanding retail stores to increase brand awareness [2][4] - A comprehensive distribution system is being established nationwide, including provincial distribution centers to support terminal sales [2][4] - Collaboration with large chains and social pharmacies is being pursued to create dedicated product displays, enriching the product variety available to consumers [4] Group 3: Sales Performance and Marketing Effectiveness - The market sales of the "An Gong Niu Huang Wan" product are meeting expectations, with a focus on promoting major product categories [4] - The company is implementing a differentiated marketing strategy for the "Royal Medicine Legend Series" and "Royal Medicine 300 Series" to enhance brand influence [4] - Continuous marketing reforms are being pursued to integrate marketing systems and improve service quality at retail outlets [4] Group 4: Medical Business Development - The company has established a medical division to expand its medical market presence, leveraging a diverse product range included in the national essential drug list [4] - Efforts include organizing academic exchange meetings and clinical evidence-based medicine verification to support medical channel development [4] Group 5: Overall Business Strategy - The company is committed to a long-term development strategy, focusing on production stability, channel construction, and market sales to promote high-quality operational growth [4]